Rapid Influenza Diagnostics Market Size & Share, by Test Type (Influenza A Test, Influenza B Test, Influenza A+B Test); End User (Hospitals, Diagnostic Centers, Research Laboratories, Office Based Settings, Nursing Home); Distribution Channel (Retail, Direct) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036
For its quick influenza diagnostic testing device, ID NOW INFLUENZA A & B 2, Abbott got U.S. FDA approval in October 2018. The influenza A and B viruses may be quickly identified and differentiated molecularly with this assay. This product approval helped the business increase its market presence and diversify its offering of influenza diagnostic tests.
The acquisition of Luminex Corporation, a business involved in the development of diagnostic tools for infectious diseases, was announced by DiaSorin SpA in April 2021. The goal of this acquisition was to increase the diagnostic goods available in the United States, including those for the diagnosis of influenza. This tactical choice helped the business grow its clientele and strengthen its position in the market.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5310
Published Date: Oct 12, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing prevalence of influenza and growing research and development are some of the major factors anticipated to drive the growth of the rapid influenza diagnostics market.
The market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2024-2036.
The major players in the market are of Abbott Laboratories, BD, F. Hoffmann-La Roche Ltd, NeuroLogica Corp., GENERAL ELECTRIC, Quest Diagnostics Incorporated, Shenzhen Mindray Bio-Medical Electronics Co., Ltd.,, and others.
The diagnostic centers segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.